VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CTNM
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CTNMContineum Therapeutics, Inc.
$9.24$345M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
CTNM logo

Contineum Therapeutics, Inc.

CTNM
NASDAQ · Immunology Biotech
$9.24
At close - Nov 18, 4:00 PM EST - USD
Market Cap$345M
P/E-5.6x
52W High$17.79
Volume204.01K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Pre-Revenue Clinical Stage Faces Critical Cash Runway

Contineum Therapeutics is a clinical-stage biotechnology company with zero revenue, entirely dependent on external financing to fund its R&D pipeline.

GrowthStable
ProfitabilityWeak
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

CTNM price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

5/12 Beats

EPS beat 5 of last 12 quarters

02

Valuation risk

-116% Peers

P/E is 116% below peer median

03

Market leadership

RS 25 · Lag

Laggard (Underperforming 75% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 3

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
CTNM-18.88%
S&P 500 (^GSPC)+6.88%
1-Year Return
CTNM-19.72%
S&P 500 (^GSPC)+10.62%
3-Year Return
CTNM-40.00%
S&P 500 (^GSPC)+56.94%
5-Year Return
CTNM-40.00%
S&P 500 (^GSPC)+51.24%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$60M-41.9% YoY
Free cash flow FY25
-$56M-66.5% YoY
Operating margin FY25
-
ROIC (FY25)-27.1%
Avg ROIC 5Y-25.8%
ROE (TTM)-25.5%
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate5/12 (45%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 3, 2026
-$0.49-8.0%
vs -$0.45
—
vs $6M
Q3 2026
Jul 30, 2026
-$0.40+10.9%
vs -$0.45
—
vs —
Q2 2026
May 5, 2026
-$0.39+29.1%
vs -$0.55
—
vs —
Q2 2026
Mar 5, 2026
-$0.49+2.0%
vs -$0.50
—
vs $8M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Business Wire·Nov 9, 2026
Qureight's Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial

CAMBRIDGE, England & SAN DIEGO--(BUSINESS WIRE)--Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum) (NASDAQ:CTNM), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight's Fibr8™ quantitative imaging biomarker is being us.

Business Wire·Nov 3, 2026
Contineum Therapeutics Reports Third-Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its third-quarter 2026 financial results. “Lysophosphatidic acid 1 receptor (LPAR1) antagonism as a treatment approach for pulmonary fibrosis has exceptionally strong clinical validation with multiple trials successfully c.

Zacks Investment Research·Oct 12, 2026
All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy

Contineum Therapeutics, Inc. (CTNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Benzinga·Oct 12, 2026
Why Is Contineum Therapeutics Stock Falling Monday?

Contineum Therapeutics Inc. (NASDAQ:CTNM) stock plunged Monday following mixed Phase 3 trial results for Bristol Myers Squibb & Co.'s (NYSE:BMY) competing lung disease drug, admilparant.

Filtered for Contineum Therapeutics, Inc.More Headlines
04

Compare before deciding

Benchmark CTNM against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Contineum Therapeutics, Inc. (CTNM)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
CTNM logoCTNMContineum Therapeutics, Inc.Current
$9.24$345.45M-5.59——-25.48%—
IMVT logoIMVTImmunovant, Inc.
$33.17$6.85B-13.47—-7173.52%-63.01%—
PRTA logoPRTAProthena Corporation plc
$8.35$437.15M-17.98-92.84%-45.43%-8.34%—
ARQT logoARQTArcutis Biotherapeutics, Inc.
$27.61$3.45B126.3091.34%5.88%14.18%—
KYMR logoKYMRKymera Therapeutics, Inc.
$121.13$9.96B-34.69-16.72%-341.87%-22.39%—
ACAD logoACADACADIA Pharmaceuticals Inc.
$17.83$3.05B8.6411.87%30.13%28.03%—

Compare CTNM vs Peers

Contineum Therapeutics, Inc. (CTNM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs IMVT

Most directly comparable listed peer for CTNM.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare CTNM against a more recognizable public peer.

Peer Set

Compare Top 5

vs IMVT, PRTA, ARQT, KYMR

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

CTNM SEC Filings & Documents

Contineum Therapeutics, Inc. (CTNM) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Jul 30, 2026·SEC

Material company update

Jul 13, 2026·SEC

Material company update

Jun 26, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 5, 2026·SEC

FY 2025

Mar 6, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Jul 30, 2026·SEC

FY 2026

May 5, 2026·SEC

FY 2025

Oct 30, 2025·SEC

Get notified when CTNM posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

CTNM Frequently Asked Questions

Contineum Therapeutics, Inc. (CTNM) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is CTNM profitable?

No. Contineum Therapeutics, Inc. (CTNM) reported a net loss of $63.5M over the trailing twelve months.

Dividend & Returns
What is CTNM's return on equity?

Contineum Therapeutics, Inc. (CTNM) had a return on equity (ROE) of -25.5% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Contineum Therapeutics, Inc.'s free cash flow?

Contineum Therapeutics, Inc. (CTNM) had negative free cash flow of $52.2M over the trailing twelve months.

What if you invested $1,000 in CTNM back in 2021?

Total return calculator · dividends reinvested · 5+ years of data

See returns →